| dc.contributor.author | George, Sarah L | |
| dc.date.accessioned | 2023-01-12T02:55:17Z | |
| dc.date.available | 2023-01-12T02:55:17Z | |
| dc.date.issued | 2016 | |
| dc.identifier.uri | https://clinicaltrials.gov/ct2/show/NCT02952833 | en_US |
| dc.identifier.uri | https://hdl.handle.net/20.500.12663/3197 | |
| dc.description.abstract | This study is a study to evaluate the safety of ZPIV. Three dose levels may be evaluated. The entire duration of each subject's participation is approximately 14 months including recruitment and collection of data on the safety and reactogenicity of the study vaccine and samples for the assessment of immunogenicity. This study is expected to take approximately 30 months to complete from initiation through availability of a final report on the primary outcomes of safety and the secondary outcomes of humoral immunity to ZIKV. The Primary objectives of this study are to 1. Assess the safety and reactogenicity of a homologous prime boost regimen of ZPIV given at three different dose levels and 2. Compare the safety and reactogenicity profile of ZPIV after each vaccination and between dosage groups. | en_US |
| dc.language | English | en_US |
| dc.subject | Zika Research Project | en_US |
| dc.subject | Zika Virus | en_US |
| dc.subject | Vaccines | en_US |
| dc.title | ZIKA Vaccine in Naive Subjects | en_US |
| eihealth.country | Others | en_US |
| eihealth.category | Epidemiology and epidemiological studies | en_US |
| eihealth.type | Research protocol information | en_US |
| eihealth.maincategory | Save Lives / Salvar Vidas | en_US |
| dc.relation.ispartofjournal | Clinical Trials | en_US |
